The same ex vivo marrow's treatment that we used in mismatched BMT (in
cubation with vincristine and methylprednisolone) was used in two pati
ents with chronic GVHD and in one patient with PRCA. The conditioning
regimen with cyclophosphamide and ALG was aimed to hill only the patie
nt's lymphocytes, and did not cause a deep myeloid aplasia. The patien
ts achieved a clear improvement of their symptoms.